This ExpertREACT article was originally published on 21 September 2009. Survey data and market positions described reflect the state of knowledge at that date.
The emerging teenage vaccine market
The US Centers for Disease Control and Prevention published its third annual NIS-Teen survey of national adolescent vaccination coverage in 2008 - a telephone-based survey expanded to cover all four quarters of the year with 17,835 records from all 50 US states. The survey indicated that overall vaccination coverage for preteens (11-12 years) and teens (13-18 years) was improving. The number of vaccines routinely recommended to US teenagers had increased significantly: meningococcal conjugate vaccine (MCV4, one dose), tetanus-diphtheria-acellular pertussis (Tdap, one dose) and for girls, quadrivalent HPV vaccine (Gardasil, three doses). Additional catch-up vaccines for missed hepatitis B, varicella and MMR were also recommended. VacZine Analytics estimated the global teenage vaccine segment at approximately $3.5-4.0bn in 2008.
Merck & Co's Gardasil launch was identified as the primary commercial driver behind the accelerating focus on teenage vaccination. With its compelling prevention case for cervical cancer and the subsequent US ACIP extension to adolescent boys - voted on in 2009 - HPV vaccination of the teenage cohort was gaining momentum internationally. However, complete three-dose coverage rates for Gardasil remained low at approximately 30% of eligible teenage girls in the US, and global policy harmonisation typically followed US ACIP recommendations with a time lag - suggesting the market was still in an early adoption phase.
A platform with further potential
VacZine Analytics concluded that the teenage segment represented a genuinely new area of vaccine revenue growth - distinct from the well-established paediatric (infant) market - and one that manufacturers were increasingly targeting with dedicated R&D and market access strategies. Teenagers were characterised as generally easier to access for vaccination than older healthy adults, with school-based programmes and clinic settings providing clear reach mechanisms. The combination of MCV4, Tdap, and HPV4 as the core recommended adolescent vaccines - alongside expected future additions - suggested the segment would grow meaningfully as coverage improved and potential new indications (such as male HPV and broader meningococcal protection) were adopted into schedules.